6-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm

IRVINE, Calif., Aug. 01, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Roche Holding AG (“Roche Holding” or the “Company”) (Other OTC:RHHBY). Investors who purchased or otherwise acquired Roche Holding shares from March 2, 2017 through June 5, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the August 7, 2017 lead plaintiff motion deadline.

If you purchased shares of Roche Holding during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the lawsuit, during the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose material information, specifically that the combination of the Company’s breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher rate of side effects. Following this news, Roche Holding’s stock price fell materially, which harmed investors according to the Complaint.

If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]